1282516-74-8

Basic information

• Product Name: 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylicacid
• Synonyms: 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylicacid;EOS-60750
• CAS NO: 1282516-74-8
• Molecular Formula: C12H9BrN2O3
• Molecular Weight: 309.13
• Mol File: 1282516-74-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylicacid(1282516-74-8)
• EPA Substance Registry System: 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylicacid(1282516-74-8)

Safety Data

• Hazardous Substances Data: 1282516-74-8(Hazardous Substances Data)

Upstream product

• 1113-59-3 bromopyruvic acid 
• 635702-31-7 4-bromo-2-fluoro-N-hydroxybenzimidamide 
• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 124-38-9 carbon dioxide 
• 1282516-69-1 9-bromo-2-iodo-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 
• 1282516-73-7 8-Bromo-4,5-dihydro-6-oxa-1,3a-diaza-benzo[e]azulene-2-carboxylic acid methyl ester 
• 1282516-68-0 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 
• 1282516-67-9 9-bromo-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 
• 1282516-66-8 5-bromo-2-(1H-imidazol-2-yl)phenol 
• 22532-62-3 4-bromosalicylaldehyde 

Downstream Products

• 1282513-03-4 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoic acid 
• 1282514-64-0 ethyl 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanoate 
• 1282512-48-4 taselisib 

Relevant articles and documents

Manufacture of the PI3K β-Sparing Inhibitor Taselisib. Part 2: Development of a Highly Efficient and Regioselective Late-Stage Process

A highly efficient and regioselective manufacturing route for the phosphoinositide 3-kinase β-sparing inhibitor taselisib was developed. Highlights of the synthesis include: (1) magnesium-mediated formation of a challenging cyclic amidine; (2) regioselect

BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE

Benzoxazepin Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.